Profitability
This table compares Reliv’ International and Silverback Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Reliv’ International | -0.61% | -1.89% | -1.31% |
| Silverback Therapeutics | N/A | -29.62% | -28.20% |
Institutional and Insider Ownership
7.8% of Reliv’ International shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 30.0% of Reliv’ International shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Reliv’ International and Silverback Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Reliv’ International | $35.06 million | 0.11 | -$440,000.00 | ($0.09) | -25.00 |
| Silverback Therapeutics | N/A | N/A | -$89.48 million | ($2.42) | -3.22 |
Reliv’ International has higher revenue and earnings than Silverback Therapeutics. Reliv’ International is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Reliv’ International has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
About Reliv’ International
Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.
About Silverback Therapeutics
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Receive News & Ratings for Reliv' International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reliv' International and related companies with MarketBeat.com's FREE daily email newsletter.
